Continuous vs intermittent adenosine 2A receptor (A2AR) inhibition in preclinical colon cancer (CC) models and in a Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with non-small cell lung cancer (NSCLC). (October 2020)

• Record Type: Journal Article
• Authors: Lin, C.C.; Joerger, M.; Grell, P.; Chiappori, A.A.; Leal, T.A.; Kasper, S.; Jerusalem, G.; Gonçalves, A.; Wolf, J.; De Braud, F.; de Jonge, M.J.A.; Otero, J.; Chhagan, S.; Cipolletta, D.; Morris, E.; Chowdhury, N.R.; Hurtado, F.K.; Tan, D.S.
• Is Part Of: European journal of cancer. Volume 138(2020)Supplement 2
• Page Start: S12
• Page End: S13
• Publication Date: 2020-10
• Subjects: Cancer -- Periodicals; Neoplasms -- Periodicals; Cancer -- Périodiques; Cancer; Tumors; Electronic journals; Periodicals; Electronic journals; 616.994
• DOI: 10.1016/S0959-8049(20)31098-4
• Languages: English
• ISSNs: 0959-8049